Aastrom Biosciences, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
13 août 2013 09h59 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Announces Amendment of Series B Preferred Stock Certificate of Designations, Preferences and Rights
12 août 2013 14h29 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Second-Quarter and First-Half 2013 Financial Results
07 août 2013 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at the JMP Securities Healthcare Conference
03 juil. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., July 3, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Reports First Quarter 2013 Financial Results
08 mai 2013 16h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 8, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom to Host First Quarter 2013 Investor Call on May 8, 2013
03 mai 2013 16h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 3, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Hold Annual Meeting of Shareholders on May 2, 2013
25 avr. 2013 16h30 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 25, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Announces First Patients Treated in ixCELL-DCM Clinical Study of ixmyelocel-T
19 avr. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at Multiple Conferences in April
09 avr. 2013 16h12 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 9, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Announces First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T
04 avr. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 4, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...